diabetic%20ketoacidosis%20-and-%20hyperosmolar%20hyperglycemic%20state
DIABETIC KETOACIDOSIS & HYPEROSMOLAR HYPERGLYCEMIC STATE
Diabetic ketoacidosis is characterized by having blood glucose >13.9 mmol/L, arterial pH <7.3 in adults or venous pH <7.3 in pediatrics, bicarbonate <15 mEg/L, moderate ketonuria or ketonemia and anion gap >14.
Hyperosmolar Hyperglycemic state in adults is described as having blood glucose >33.3 mmol/L, arterial pH >7.3, bicarbonate >15 mEq/L, mild ketonuria or ketonemia, effective serum osmolality >320 mOsm/kg and variable anion gap.
While hyperosmolar Hyperglycemic state in pediatric patients have blood glucose >33.3 mmol/L, venous pH >7.3, bicarbonate >15 mEq/L and altered mental status or severe dehydration.

Pharmacotherapy

Intravenous (IV) Fluids

  • Initial therapy aims to restore renal perfusion, & expand intravascular & extravascular volume
  • Fluid deficits should be corrected w/in the first 24 hours of treatment
  • Serum Na should be corrected for hyperglycemia (for each 5.6 mmol/L glucose >5.6 mmol/L, add 1.6 mmol to Na value for corrected serum Na value)
  • Serum osmolality change should not be >3 mOsm/kg H2O/hour
  • Avoid iatrogenic fluid overload by frequently monitoring cardiac, renal & mental status
  • In pediatric patients, initial fluid expansion should not be >50 mL/kg over first 4 hours of treatment
    • Fluid deficits should be corrected over 48 hours of treatment

Insulin

  • Ketonemia usually takes longer to clear than hyperglycemia
  • There should be an overlap of IV insulin & subcutaneous (SC) insulin of 1-2 hours to ensure adequate glucose control
    • An abrupt discontinuation of IV insulin w/ a delayed onset of SC insulin may result in inadequate glucose control
  • In newly diagnosed diabetics the initial total insulin dose should be ~0.5-1 U/kg/day given in ≥2 divided doses
    • Include both short-acting & long-acting insulin
    • Continue until optimal dosing is established

Potassium

  • Correction of acidosis, volume expansion & insulin therapy decrease serum K concentration
    • Hypokalemia may be avoided by K replacement 
  • If patient presents w/ severe hypokalemia, insulin treatment should be delayed until K serum concentration is restored to >3.3 mmol/L to avoid respiratory arrest & arrhythmias

Bicarbonate

  • Studies have failed to show benefit or deleterious changes in morbidity or mortality w/ bicarbonate use in diabetic ketoacidosis (DKA) patients w/ pH between 6.9-7.1
  • Insulin & bicarbonate can lower serum K & supplementation may be required

Phosphate

  • Patients w/ cardiac dysfunction, anemia or respiratory depression may benefit from careful phosphate replacement
    • Hypophosphatemia may cause cardiac & skeletal muscle weakness, & respiratory depression

Somatostatin

  • Though not considered standard therapy, Somatostatin may be added if patients are resistant to conventional DKA therapy
  • Effects: Decrease glucagon secretion & inhibit ketogenesis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.